AURA vs NVS vs REGN vs PFE

For growth investors, Novartis AG (NVS) is the stronger pick with 6.

0% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 14. 8x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate Aura Biosciences, Inc. (AURA) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Regeneron Pharmaceuticals, Inc.

(REGN) is the cheapest at 14. 8x versus Novartis AG at 21. 3x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Novartis AG wins at 1. 14x versus Regeneron Pharmaceuticals, Inc. 's 2. 08x — a reasonable growth-adjusted valuation.

Over the past 5 years, Novartis AG (NVS) delivered a total return of +94.

0%, compared to -56. 7% for Aura Biosciences, Inc. (AURA). Over 10 years, the gap is even starker: NVS returned +187. 2% versus AURA's -56. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pfizer Inc.

(PFE) is the lower-risk stock at 0. 38β versus Aura Biosciences, Inc. 's 1. 68β — meaning AURA is approximately 345% more volatile than PFE relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 80% for Novartis AG — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Novartis AG (NVS) is pulling ahead at 6.

0% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: Novartis AG grew EPS 22. 5% year-over-year, compared to -3. 5% for Pfizer Inc.. Over a 3-year CAGR, NVS leads at 8. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus 0. 0% for Aura Biosciences, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVS leads at 31. 2% versus 0. 0% for AURA. At the gross margin level — before operating expenses — REGN leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Novartis AG (NVS) is the more undervalued stock at a PEG of 1. 14x versus Regeneron Pharmaceuticals, Inc. 's 2. 08x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Pfizer Inc. (PFE) trades at 8. 9x forward P/E versus 17. 5x for Novartis AG — 8. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AURA: 165. 2% to $17. 00.

In this comparison, PFE (6.

6% yield), NVS (2. 6% yield), REGN (0. 6% yield) pay a dividend. AURA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Novartis AG (NVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

45), 2. 6% yield, +187. 2% 10Y return). Aura Biosciences, Inc. (AURA) carries a higher beta of 1. 68 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NVS: +187. 2%, AURA: -56. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AURA is a small-cap quality compounder stock; NVS is a large-cap quality compounder stock; REGN is a mid-cap deep-value stock; PFE is a mid-cap income-oriented stock. NVS, REGN, PFE pay a dividend while AURA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.